Business
Typewriter emerges with USD 56m to build non-viral in vivo CAR-T platform
Cambridge, Massachusetts-based Typewriter Therapeutics, Inc. has emerged from stealth with a USD 56 million Series A financing round to advance a non-viral,...
Novartis taps Alteogen in USD 3.2b subcutaneous biologics pact
Novartis has entered an option and license agreement with South Korea-based Alteogen Inc. (KOSDAQ: 196170) to develop and commercialize subcutaneous...
Keymed licenses approved IL-4Ralpha mAb stapokibart to Singapore firm Aeira for 18 Asian markets
Keymed Biosciences Inc. (HKEX: 02162) has licensed its approved IL-4Rα monoclonal antibody stapokibart (Kangyueda) to Singapore-based Aeira Pte. Ltd. for...
Korea's Pharos iBio, Kolon Pharma advance fourth-generation EGFR inhibitor into preclinical
South Korea-based Pharos iBio and Kolon Pharma have signed a joint research and development agreement to co-develop PHI-701, a preclinical EGFR-targeting...
Takeda taps Weave Bio for AI regulatory automation across 14 drug programs
San Francisco-based Weave Bio and Takeda have announced a collaboration to deploy Weave's AI-native regulatory automation platform across 14 of Takeda's...
Vertex closes USD 10b Crinetics deal to establish endocrinology as fifth therapeutic pillar
Vertex Pharmaceuticals (Nasdaq: VRTX) completed its acquisition of Crinetics Pharmaceuticals on September 1, 2026, adding a commercially launched rare...
Ono Pharma taps Aitia's causal AI to identify neurological disease targets
Ono Pharmaceutical Co., Ltd. and Cambridge, Massachusetts-based Aitia, Inc. have announced a drug discovery partnership covering neurological diseases,...
Evotec and Plectonic combine T-cell platforms to tackle solid tumor selectivity challenge
Combining two preclinical platform technologies that each address a distinct failure mode of T-cell engager therapy in solid tumors, Evotec SE (Nasdaq: EVO)...
Convergen raises USD 15m to advance tau-targeting protein degradation platform
Suzhou-based Convergen has closed a USD 15 million Seed+ financing round to advance its TrimTAC targeted protein degradation platform for neurodegenerative...
EIT Pharma secures USD 35m Series A to advance lonafarnib in hepatitis D
Washington-based EIT Pharma, Inc. has closed an oversubscribed USD 35 million Series A financing round to support the late-stage regulatory review of...
Kazia raises USD 40m upfront, links another USD 80m to breast cancer readouts
Australia-based Kazia Therapeutics Limited (Nasdaq: KZIA) closed an oversubscribed, tranched registered public offering generating USD 40 million in upfront...
PMV Pharma raises USD 50.8m to fund rezatapopt NDA submission in Q1 2027
Princeton, New Jersey-based PMV Pharmaceuticals (Nasdaq: PMVP) announced an oversubscribed public offering expected to raise approximately USD 50.8 million...
RedHill exits Talicia for USD 18m upfront to fund GI portfolio expansion
RedHill Biopharma (Nasdaq: RDHL) has divested its 70% stake in Talicia, an FDA-approved H. pylori eradication therapy, to a subsidiary of Canada-based...
Revelyx launches with recombinant botulinum toxin ready for Phase II readout
Nashville-based Revelyx Bio has launched as a clinical-stage company built around an exclusive license from China-based Chongqing Claruvis Pharmaceutical...
Lilly snaps up Merida in USD 2.9b autoimmune deal
Eli Lilly has agreed to acquire Cambridge, Massachusetts-based Merida Biosciences, Inc., a private precision immunology company, for up to USD 2.875 billion...
The AllSci Brief
Free, systematic R&D and deal news. Daily.